Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02496663
Title Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
Stanford Cancer Institute Palo Alto Palo Alto California 94304 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
UCHealth University of Colorado Hospital Aurora Colorado 80045 United States Details
MedStar Georgetown University Hospital Washington District of Columbia 20007 United States Details
Emory University Hospital Midtown Atlanta Georgia 30308 United States Details
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322 United States Details
Emory Saint Joseph's Hospital Atlanta Georgia 30342 United States Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 United States Details
Brigham and Women's Hospital Boston Massachusetts 02115 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Duke Cancer Institute Cary Cary North Carolina 27518 United States Details
Duke University Medical Center Durham North Carolina 27710 United States Details
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field